Clinical Trial Detail

NCT ID NCT03970447
Title A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Global Coalition for Adaptive Research
Indications

glioblastoma multiforme

gliosarcoma

Therapies

Lomustine

Regorafenib

Temozolomide

Age Groups: senior adult

Additional content available in CKB BOOST